^
Association details:
Biomarker:HLA-A*01
Cancer:Non Small Cell Lung Cancer
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

184P - Patient-specific HLA-I genotypes predict response to immune checkpoint blockade

Published date:
10/16/2023
Excerpt:
In the NSCLC subgroup, patients with HLA-A01 subtypes were significantly associated with better OS (hazard ratio (HR): 0.42, 95%CI: 0.22-0.81, p= 0.010); meanwhile, HLA-A02 was associated with worse OS (HR: 1.95, 95%CI: 1.09-3.49, p= 0.024)...HLA-A status predicted clinical outcomes of patients receiving ICB.